In many cancer centres, immediate or post-chemotherapy bilateral mastectomy has become an almost routine recommendation for BRCA1 and BRCA2 mutation carriers regardless of the size or focality of the presenting tumour. This evidence concerns the gene BRCA2 and neoplasm.